Hormone-Diabetes combo could boost blood sugar control in menopause

NCT ID NCT06715514

Recruiting now Disease control Sponsor: Lia Bally Source: ClinicalTrials.gov ↗

First seen Jun 13, 2026 · Last updated Jun 19, 2026 · Updated 2 times

Summary

This study looks at whether adding menopausal hormone therapy (MHT) to a GLP-1 receptor agonist (a type of diabetes drug) helps control blood sugar and weight better than the diabetes drug alone. It involves 96 early postmenopausal women who have or are at risk for type 2 diabetes. Participants will receive either the combination therapy or the diabetes drug alone, and researchers will measure changes in blood sugar levels over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University Hospital Bern
RECRUITING

Bern, 3010, Switzerland

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

diabetes mellitus prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENOPAUSE TYPE 2 DIABETES